ProKidney Corp. (PROK)
Oxford Ledge is still expanding full research coverage of PROK. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Late-stage biotech company developing an autologous cell therapy to preserve kidney function in patients with advanced chronic kidney disease and diabetes.
SEC filings
- 8-K Shareholder vote results 2026-05-29
- 8-K Results of operations / financial condition; Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-05-15
- 10-Q Quarterly financial report (unaudited) 2026-05-15
- DEF 14A Proxy statement for shareholder vote 2026-04-17
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-03-18
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for PROK. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open PROK in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.